摘要目的:探讨基于维奈托克的治疗方案对t（11；14）复发难治多发性骨髓瘤（RRMM）患者的治疗效果。方法:回顾性分析海军军医大学长征医院2019年6月收治的1例接受基于维奈托克治疗方案的t（11；14）RRMM患者资料，并进行相关文献复习。结果:该t（11；14）RRMM患者经三线治疗进展后，予以选择性bcl-2抑制剂维奈托克联合达雷妥尤单抗、地塞米松治疗，疾病达到部分缓解，且一度血象恢复，美国东部肿瘤协作组（ECOG）体能状态评分由3分下降至1分，生命质量明显改善。结论:t（11；14）RRMM患者可从基于维奈托克的治疗中获益，未来尚需对维奈托克治疗多发性骨髓瘤的安全性、敏感性等进行深入探索。

abstractsObjective:To explore the effect of venetoclax-based therapy on relapsed/refractory multiple myeloma (MM) patients harboring t(11;14).Methods:The data of a relapsed/refractory MM patient harboring t(11;14) treated with venetoclax-based regimen admitted to Shanghai Changzheng Hospital in June 2019 was retrospectively analyzed and the literatures were reviewed.Results:The relapsed/refractory MM patient harboring t(11;14) had progression of disease after 3 lines of therapies, and then was treated with the selective bcl-2 inhibitor venetoclax combined with daratumumab and dexamethasone. As a result, the patient achieved partial remission and better hemogram recovery. The Eastern Cooperative Oncology Group (ECOG) score of physical status decreased from 3 to 1, and the quality of life was improved significantly.Conclusions:The relapsed/refractory MM patients harboring t(11;14) could benefit from venetoclax-based therapy. In the future, the safety, sensitivity and other performances of venetoclax in the treatment of MM should be further explored.